Trial · NCT02137317
Farming, Personal Protective Equipment, Nepal
NCT02137317, Not applicable, Completed, Bispebjerg Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Farming, Personal Protective Equipment, Nepal. Trials, record NCT02137317. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02137317
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Farming, Personal Protective Equipment, Nepal
- NCT number
- NCT02137317
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 45 participants, actual
- Lead sponsor
- Bispebjerg Hospital
- Conditions
- Organophosphate Poisoning
- Interventions
- LAPPE (locally adapted personal protective equipment)
- First posted
- 2014-05-13
- Last updated
- 2015-02-23
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Cholinesterase | Farmers will be followed over 15 days (cholinesterase measured four times) | Plasma cholinesterase is a substance necessary for the proper functioning of the human nervous system. The inhibition of this type of cholinesterase is considered as a useful indicator of exposure to organophosphates when measured before and after likely exposure. Plasma cholinesterase will be measured with a Test-mate Cholinesterase System (Model 400) requiring 10 microliters (µL) for a blood test. |
| Secondary | Acute Organophosphate Poisoning Symptoms | Farmers will be followed for 15 days (symptoms measured four times) | The World Health Organization has constructed a clinical representation of acute organophosphate poisoning consisting of: headache, dizziness, bradycardia, weakness, anxiety, excessive sweating, fasciculations, abdominal cramps, dyspnea, miosis, paralysis, salivation, tearing, ataxia, pulmonary edema, vomiting, diarrhea, confusion, acetyl cholinesterase inhibition. In the present study, all clinical representations except from acetyl cholinesterase inhibition will be evaluated as self-reported acute organophosphate poisoning symptoms. However, some of the clinical representations may be difficult for the farmers' to report themselves and therefore such clinical representations have been translated into more understandable terms. Furthermore, symptoms are added based on local health care experience. In a survey information on self-reported acute organophosphate poisoning symptoms will be retrieved with yes/no response options as has been seen in previous studies. |
| Other | Feasibility | Farmers will be followed over 15 days (measured two times) | In the survey the feasibility of the LAPPE solution (locally adapted personal protective equipment) is measured with yes/no response options: "Was it comfortable?", "Did it feel hotter?", "Any problem when spraying?" and "Did you like garments?". With minor adjustments the same questions will be posed to the farmers in the present study to measure the feasibility of the LAPPE and DP solutions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02137317
GET https://conductscience.org/api/trials/v1/NCT02137317/papers?page=2